The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes
Floris Dammeijer(Erasmus MC), Joachim G.J.V. Aerts(Radboud University Nijmegen), Cornelis Verhoef(Erasmus MC Cancer Institute), Yvette van Kooyk(Amsterdam University Medical Centers), Yvonne M. Mueller(Erasmus MC), Ralph Stadhouders(Erasmus MC), Louis Boon, Melanie Lukkes(Erasmus MC), Larissa Klaase(Erasmus MC), Peter D. Katsikis(Drexel University), Thierry van den Bosch(Erasmus MC), Sai Ping Lau(Erasmus MC), Heleen Vroman(Bravis Ziekenhuis), Kitty Latupeirissa(Erasmus MC), Evalyn E.A.P. Mulder(Erasmus MC), Rudi W. Hendriks(Erasmus MC), Alexander M.M. Eggermont(University Medical Center Utrecht), Thorbald van Hall(Leiden University Medical Center), Mandy van Gulijk(Erasmus MC), Menno van Nimwegen(Erasmus MC), Dirk J. Grünhagen(Erasmus MC), Sjoerd Schetters(Ghent University), Antien Moyaart(Erasmus MC), Jan H. von der Thüsen(Erasmus MC)
Cited by 683
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k